Eddie Zhang1, Lora Wang2, Talha Shaikh1, Elizabeth Handorf3, J Karen Wong1, John P Hoffman4, Sanjay Reddy4, Harry S Cooper5, Steven J Cohen6, Efrat Dotan7, Joshua E Meyer8. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 2. Department of Radiation Oncology, University of Miami, Miami, FL, USA. 3. Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA. 4. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 5. Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA. 6. Department of Medical Oncology, Abington Hospital/Jefferson Health, Abington, PA, USA. 7. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 8. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. joshua.meyer@fccc.edu.
Abstract
BACKGROUND: Many studies show significantly improved survival after R0 resection compared with R1 resection in pancreatic adenocarcinoma (PAC); however, the effect of neoadjuvant chemoradiation (NACRT) on this association is unknown. OBJECTIVE: The aim of this study was to evaluate the prognostic significance of positive surgical margins (SMs) after NACRT compared with upfront surgery + adjuvant therapy in PAC. METHODS: All cases of surgically resected PAC at a single institution were reviewed from 1996 to 2014; patients treated with palliative intent, metastatic disease, and biliary/ampullary tumors were excluded. The primary endpoint was overall survival (OS). RESULTS: Overall, 300 patients were included; 134 patients received NACRT with concurrent 5-fluorouracil or gemcitabine followed by surgery, and 166 patients received upfront surgery (+ adjuvant chemotherapy in 72% of patients and RT in 65%); 31% of both groups had a positive SM (+SM). The median OS for patients with a +SM or negative SM (-SM) was 26.6 and 31.6 months, respectively for NACRT, and 12.0 and 24.5 months, respectively, for upfront surgery. OS was significantly improved with -SM compared with +SM in both groups (p = 0.006). When resection yielded +SM, NACRT patients had improved OS compared with upfront surgery patients (p < 0.001). On multivariable analysis, +SM in the upfront surgery group (hazard ratio [HR] 2.94, 95% confidence interval [CI] 2.04-4.24; p < 0.001) and older age (HR 1.01, 95% CI 1.00-1.03, per year; p = 0.007) predicted worse OS. +SM in the NACRT group was not associated with worse OS (HR 1.09, 95% CI 0.72-1.65; p = 0.70). CONCLUSION: Patients with a positive margin after NACRT and surgery had longer survival compared with patients with a positive margin after upfront surgery. NACRT should be strongly considered for patients at high risk of R1 resections.
BACKGROUND: Many studies show significantly improved survival after R0 resection compared with R1 resection in pancreatic adenocarcinoma (PAC); however, the effect of neoadjuvant chemoradiation (NACRT) on this association is unknown. OBJECTIVE: The aim of this study was to evaluate the prognostic significance of positive surgical margins (SMs) after NACRT compared with upfront surgery + adjuvant therapy in PAC. METHODS: All cases of surgically resected PAC at a single institution were reviewed from 1996 to 2014; patients treated with palliative intent, metastatic disease, and biliary/ampullary tumors were excluded. The primary endpoint was overall survival (OS). RESULTS: Overall, 300 patients were included; 134 patients received NACRT with concurrent 5-fluorouracil or gemcitabine followed by surgery, and 166 patients received upfront surgery (+ adjuvant chemotherapy in 72% of patients and RT in 65%); 31% of both groups had a positive SM (+SM). The median OS for patients with a +SM or negative SM (-SM) was 26.6 and 31.6 months, respectively for NACRT, and 12.0 and 24.5 months, respectively, for upfront surgery. OS was significantly improved with -SM compared with +SM in both groups (p = 0.006). When resection yielded +SM, NACRT patients had improved OS compared with upfront surgery patients (p < 0.001). On multivariable analysis, +SM in the upfront surgery group (hazard ratio [HR] 2.94, 95% confidence interval [CI] 2.04-4.24; p < 0.001) and older age (HR 1.01, 95% CI 1.00-1.03, per year; p = 0.007) predicted worse OS. +SM in the NACRT group was not associated with worse OS (HR 1.09, 95% CI 0.72-1.65; p = 0.70). CONCLUSION: Patients with a positive margin after NACRT and surgery had longer survival compared with patients with a positive margin after upfront surgery. NACRT should be strongly considered for patients at high risk of R1 resections.
Authors: Julio Garcia-Aguilar; David D Smith; Karin Avila; Emily K Bergsland; Peiguo Chu; Richard M Krieg Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Talha Shaikh; Karen Ruth; Walter J Scott; Barbara A Burtness; Steven J Cohen; Andre A Konski; Harry S Cooper; Igor Astsaturov; Joshua E Meyer Journal: Ann Thorac Surg Date: 2014-11-18 Impact factor: 4.330
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Kimberly M Brown; Veeriah Siripurapu; Marson Davidson; Steven J Cohen; Andre Konski; James C Watson; Tiaynu Li; Vince Ciocca; Harry Cooper; John P Hoffman Journal: Am J Surg Date: 2008-03 Impact factor: 2.565
Authors: Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh Journal: Histopathology Date: 2009-09 Impact factor: 5.087
Authors: Matthew H G Katz; Fang-Shu Ou; Joseph M Herman; Syed A Ahmad; Brian Wolpin; Robert Marsh; Spencer Behr; Qian Shi; Michael Chuong; Lawrence H Schwartz; Wendy Frankel; Eric Collisson; Eugene J Koay; JoLeen M Hubbard; James L Leenstra; Jeffrey Meyerhardt; Eileen O'Reilly Journal: BMC Cancer Date: 2017-07-27 Impact factor: 4.430